Literature DB >> 24449310

The accelerated approval of oncologic drugs: lessons from ponatinib.

Vinay Prasad1, Sham Mailankody1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24449310     DOI： 10.1001/jama.2013.284531

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  16 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

2.  Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.

Authors:  Anand P Singh; Michael S Glennon; Prachi Umbarkar; Manisha Gupte; Cristi L Galindo; Qinkun Zhang; Thomas Force; Jason R Becker; Hind Lal
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

3.  The hazards of rapid approval of new drugs.

Authors:  Jennifer Martin; Gillian Shenfield
Journal:  Aust Prescr       Date:  2016-02-01

4.  A further strategy to combat the high price of anticancer drugs.

Authors:  Vinay Prasad; Kevin De Jesús; Sham Mailankody
Journal:  Nat Rev Clin Oncol       Date:  2017-08-22       Impact factor: 66.675

5.  Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.

Authors:  Vinay Prasad; Sham Mailankody
Journal:  JAMA Intern Med       Date:  2017-11-01       Impact factor: 21.873

6.  Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity.

Authors:  Syed Ahmad; Gary L Johnson; John E Scott
Journal:  Biochem Biophys Res Commun       Date:  2015-06-06       Impact factor: 3.575

7.  Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

Authors:  Tri Nguyen; Elisa Hawkins; Akhil Kolluri; Maciej Kmieciak; Haeseong Park; Hui Lin; Steven Grant
Journal:  Leuk Res       Date:  2014-11-11       Impact factor: 3.156

8.  High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.

Authors:  Arun Sharma; Paul W Burridge; Wesley L McKeithan; Ricardo Serrano; Praveen Shukla; Nazish Sayed; Jared M Churko; Tomoya Kitani; Haodi Wu; Alexandra Holmström; Elena Matsa; Yuan Zhang; Anusha Kumar; Alice C Fan; Juan C Del Álamo; Sean M Wu; Javid J Moslehi; Mark Mercola; Joseph C Wu
Journal:  Sci Transl Med       Date:  2017-02-15       Impact factor: 17.956

Review 9.  Zebrafish as a Model for In-Depth Mechanistic Study for Stroke.

Authors:  Weijie Chen; Lv Xie; Fang Yu; Yan Li; Chen Chen; Wanqing Xie; Tingting Huang; Yueman Zhang; Song Zhang; Peiying Li
Journal:  Transl Stroke Res       Date:  2021-05-29       Impact factor: 6.829

10.  Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase.

Authors:  Taylor K Johnson; Daniel A Bochar; Nathalie M Vandecan; Jessica Furtado; Michael P Agius; Sameer Phadke; Matthew B Soellner
Journal:  Angew Chem Int Ed Engl       Date:  2021-08-11       Impact factor: 16.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.